These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4665550)

  • 21. [Intravenous and oral galactose loading of rats suffering from galactosamine hepatitis and ANIT-cholestasis; comparison of the kinetics in vivo and the galactose metabolism in the liver in vitro (author's transl)].
    Richter E; Hofstetter GJ; Seifert H
    Z Gastroenterol; 1979 Oct; 17(10):713-21. PubMed ID: 524947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of liver-RES on toxic liver damage due to galactosamine.
    Grün M; Liehr H; Grün W; Rasenack U; Brunswig D
    Acta Hepatogastroenterol (Stuttg); 1974 Feb; 21(1):5-15. PubMed ID: 4450963
    [No Abstract]   [Full Text] [Related]  

  • 23. [Liver glutathione and ligandin in carbon tetrachloride poisoning].
    Di Simplicio P; Palmi M; Segre G
    Boll Soc Ital Biol Sper; 1978 Nov; 54(22):2241-7. PubMed ID: 754720
    [No Abstract]   [Full Text] [Related]  

  • 24. Influence of d-galactosamine hydrochloride on lipids and their fatty acid composition in plasma and liver of guinea pigs.
    Gallenkamp H; Bartsch GG; Löhr JP; Brachtel D; Richter E
    Acta Hepatogastroenterol (Stuttg); 1976 Feb; 23(1):3-9. PubMed ID: 1258600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An investigation of the hepatotoxicity of D-galactosamine in different species of animal.
    James GW; Pickering RW; Parker FL
    Arzneimittelforschung; 1975 Oct; 25(10):1593-4. PubMed ID: 1243045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aggravating and protecting effects of triton and corticosteroids in galactosamine-induced hepatitis.
    Grases PJ; Lesch R; Stein U; Heissmeyer H; Reutter W
    G E N; 1972; 27(1):77-89. PubMed ID: 4632028
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect of the liver protecting compound ES 914 on D-galactosamine induced experimental hepatitis in the rat].
    Wegmann A; Chariatte N; Renker H; Dittrich A
    Arzneimittelforschung; 1979; 29(1):68-70. PubMed ID: 582121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Behavior of 125-I-fibrinogen and 131-I-albumin in experimental galactosamine hepatitis].
    von Mahn I; Merkel H; Sattler EL; Müller-Berghaus G
    Verh Dtsch Ges Inn Med; 1974; 80():437-9. PubMed ID: 4454578
    [No Abstract]   [Full Text] [Related]  

  • 29. Rat alpha 1-fetoprotein: appearance after galactosamine-induced liver injury.
    Sell S; Reynolds RD; Reutter W
    J Natl Cancer Inst; 1974 Jul; 53(1):289-91. PubMed ID: 4835112
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pathology caused by antibiotics. V. Hepatic lesions. Interference with hepatic production of bilirubin and induction of the enzyme systems of the hepatocytes].
    Gioannini P
    Minerva Med; 1979 Jun; 70(29):2043-8. PubMed ID: 379699
    [No Abstract]   [Full Text] [Related]  

  • 31. Increased activity of enzymes for de novo pyrimidine biosynthesis after orotic acid administration.
    Bresnick E; Mayfield ED; Mossé H
    Mol Pharmacol; 1968 Mar; 4(2):173-80. PubMed ID: 5645613
    [No Abstract]   [Full Text] [Related]  

  • 32. [Glycoprotein metabolism in galactosamine-induced hepatitis].
    Reutter W; Keppler D; Lesch R; Decker K
    Verh Dtsch Ges Inn Med; 1969; 75():363-5. PubMed ID: 5400154
    [No Abstract]   [Full Text] [Related]  

  • 33. Trimethadione as a model drug for the evaluation of hepatic drug-metabolizing capacity in normal and D-galactosamine intoxicated rats.
    Tanaka E; Kinoshita H; Yoshida T; Kuroiwa Y
    Jpn J Pharmacol; 1982 Dec; 32(6):1182-5. PubMed ID: 7161969
    [No Abstract]   [Full Text] [Related]  

  • 34. Cytoplasmic aggregates in D-galactosamine induced liver injury.
    Tompa A; Lapis K; Schaff Z; Mészáros K; Mandl J; Garzó T; Antoni F
    Acta Morphol Acad Sci Hung; 1977; 25(4):239-57. PubMed ID: 617770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Early changes in the liver under the effect of aflatoxin].
    Pokrovskiĭ AA; Meshkov NV; Kravchenko NV
    Arkh Patol; 1973; 35(8):57-60. PubMed ID: 4781614
    [No Abstract]   [Full Text] [Related]  

  • 36. Early, reversible plasma membrane injury in galactosamine-induced liver cell death.
    El-Mofty SK; Scrutton MC; Serroni A; Nicolini C; Farber JL
    Am J Pathol; 1975 Jun; 79(3):579-96. PubMed ID: 1137005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of galactosamine on the activity of lysosomal peptidehydrolases of the liver depending on the age of rats.
    Heissmeyer H; Stein U; Grub R; Reutter W; Lesch R
    Horm Metab Res; 1973 Mar; 5(2):93-7. PubMed ID: 4707707
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of inflammation on peroxisomal enzyme activities, catalase synthesis, and lipid metabolism.
    Canonico PG; Rill W; Ayala E
    Lab Invest; 1977 Nov; 37(5):479-86. PubMed ID: 21326
    [No Abstract]   [Full Text] [Related]  

  • 39. Protecting action of aspartate on the hepatic changes induced by D-galactosamine.
    Fodor O; Schvartz M; Suciu A; Barbarino F; Duca S; Lezeu R
    Arzneimittelforschung; 1976; 26(5):855-8. PubMed ID: 183787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Protective and curative effects of diethyldithiocarbamate on galactosamine hepatitis in the rat (author's transl)].
    Homann J; Gerhardt H; Hopf F
    Arzneimittelforschung; 1980; 30(4):645-7. PubMed ID: 6249330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.